Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 11/20 | 0.33 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 3/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.30 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30365748 | 0.82 | TGFBR1 (0.39) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL29694438 | 0.78 | BCHE (0.39) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL24568732 | 0.78 | BCHE (0.39) | TGFBR1ACVR1BACVRL1CYP3A4 | |
| SCHEMBL27193167 | 0.78 | TGFBR1 (0.55) | TGFBR1ACVR1BACVRL1CYP3A4CYP2C8 | |
| SCHEMBL29694392 | 0.77 | CYP11B2 (0.40) | CYP3A4 | |
| SCHEMBL24569034 | 0.77 | CYP11B2 (0.40) | CYP3A4 | |
| SCHEMBL24568731 | 0.74 | TGFBR1 (0.30) | TGFBR1ACVR1BACVRL1 | |
| SCHEMBL24569039 | 0.73 | TGFBR1 (0.36) | TGFBR1ACVR1BACVRL1CYP3A4PTGES | |
| SCHEMBL24569024 | 0.72 | — | — | |
| SCHEMBL1446578 | 0.66 | PTPN1 (0.30) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4182322-B1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARM SPA (IT) | 2024-04-24 | — | — | EP | disclosed |
| US-20240116947-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-04-11 | — | — | US | disclosed |
| EP-4182322-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116947-A1 | PYRIDO OXAZINE DERIVATIVES AS ALK5 INHIBITORS | TGFBR1, ACVR1, TGFBR2 | TGFBR1 1/4885ACVR1B 8/4885ACVRL1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.